Apyx Medical Corporation · NASDAQ:APYX
Apyx Medical — Investor Presentation (August 2023)
27 slides from Apyx Medical's investor presentation, August 2023
Slide 1: Investor Presentation
Investor Presentation August 2023 1
Slide 2: Cautionary Statements
Cautionary Statements disruptions; changes in general economic, business or demographic conditions or trends; changes in and Forward-Looking Statements effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or Certain matters discussed in this present
Slide 3: Apyx Medical at a Glance
Apyx® Medical at a Glance An advanced energy technology company, Ticker (Nasdaq) : APYX known for our Renuvion® helium plasma technology, with a passion for elevating Market Cap : ~$152M(1) people’s lives through innovative products in the cosmetic surgery market. Avg. Daily Vol (LTM) : ~260,000(2)
Slide 4: Value Proposition
Value Proposition With game-changing results in hundreds of thousands of cosmetic surgery procedures, supported by evidence-based outcomes, Renuvion has gained strong commercial traction and support from the surgeon community. Apyx Medical Corporation has embarked on a growth strategy to drive adopt
Slide 5: Investment Highlights
Investment Highlights • ~$3 billion addressable market opportunity in • Sales growth in the global cosmetic surgery the U.S. alone, including an annual opportunity market fueled by strong adoption and utilization in excess of $700 million based on the number trends. of procedures performed each year
Slide 6: Experienced Leadership Team
Experienced Leadership Team Charlie Goodwin Joined Apyx: Tara Semb Joined Apyx: Todd Hornsby Joined Apyx: Moshe Citronowicz Joined Apyx: Chief Executive Officer Dec. 2017 Chief Financial Officer, Dec. 2018 Executive Vice President Global Aug. 2014 Senior Vice President Oct. 1993 25+ Years Experience
Slide 7: U.S. Market Opportunity
U.S. Market Opportunity GENERATORS HANDPIECES ~$2.3B ~$750M Potential market Potential opportunity annual market opportunity ~$550M 2 ~$200M 3 ~15,0001 > 1 million annual surgical > 400K annual non- plastic surgeons, procedures surgical procedures cosmetic surgeons, • ~400K annual liposuction & derm
Slide 8: What is Renuvion?
What is Renuvion? Renuvion Apyx One Generator and How The Device Works Handpieces Handpiece inserted sub-dermally Contract skin via direct heating Longer-term skin contraction through neocollagenesis 8
Slide 9: The Dilemma
The Dilemma The optimal temperature for subdermal tissue contraction is 85°C. Most standard monopolar and bipolar radiofrequency devices can’t reach this temperature quickly enough without causing a concerning rise in skin temperature.1-5 1. Feldman LS, et al. (eds). The SAGES Manual on the Fundamen
Slide 10: Compelling Clinical and Real-World Evidence
Compelling Clinical and Real-World Evidence The safety and efficacy of Renuvion is supported by more than 85 published clinical papers, abstracts and posters, as well as 2 multi-site IDE clinical studies. Clinical Publications at: https://physicians.renuvion.com/library/ 10
Slide 11: Real Results
Real Results Skin Laxity Facial Renewal Before After Before After Patient: 65-year-old-female Patient: 55-year-old-female Results from IDE Clinical Study* where Results from IDE Clinical Study*, Renuvion was the only technology used. using a single-pass technique. *NCT04146467 on clinicaltrials.gov
Slide 12: 4 New Specific FDA Clinical Indications and 4 FDA Product Clearances in 12 Months
4 New Specific FDA Clinical Indications and 4 FDA Product Clearances in 12 Months Jan 2019 May 2022 Oct 2022 Apr 2023 Changed Company 510(k) Clearance 510(k) 510(k) Clearance name to APYX® for Facial Clearance for for Specific Use Medical Renewal and the the Apyx One after Liposuction Derm Handpiece
Slide 13: Global Presence
Global Presence U.S.: • Direct sales model of: • 36 field-based selling professionals • 4 sales managers • 3 independent sales agencies • Driving growth by expanding Contract Manufacturing customer base and increasing Partner utilization from existing accounts We are also registered to sell our prod
Slide 14: Strong Track Record of Advanced Energy Sales Growth
Strong Track Record of Advanced Energy Sales Growth Fueled by Adoption and Utilization of Renuvion in the Global Cosmetic Surgery Market 14 Represents Midpoint of 2023 Guidance
Slide 15: 2023 Strategic Initiatives
2023 Strategic Initiatives ☑ Advance our regulatory strategy by securing targeted clearances that address the 2022 Safety Communication ☐ Enhance product portfolio by bringing new technologies to the market ☐ Expand library of clinical evidence supporting the use of our Advanced Energy products ☐ Ma
Slide 16: Launch of First Global Direct to Consumer Brand Campaign
In January 2023, we launched our first global direct to consumer brand campaign 16
Slide 17: Financial Summary
pyx MEDICAL Financial Summary
Slide 18: Financial Highlights – Income Statement
Financial Highlights – Income Statement 18
Slide 19: FY'23 Financial Guidance
FY’23 Financial • Total revenue in the range of $59 million to $62 million, up Guidance ~ 33% to 39% year-over-year. • Total revenue guidance assumes: • Advanced Energy revenue of $51 million to $54 million, up ~ 39% to 47% year- over-year, • OEM revenue of ~$8 million, ~ 4% year-over-year • Net los
Slide 20: Appendix
\pyx MEDICAL Appendix
Slide 21: Regulatory Clearances for Target Indications
Regulatory Clearances for Target Indications • 510(k) Received April 28, 2023: Renuvion is the only device FDA cleared for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. • 510(k) Received February 23. 2023: Renuvion is the only device FDA cleared for th
Slide 22: Renuvion in the Media
Renuvion in the Media Renuvion mentioned by Dr. Paul Nassif in People Renuvion featured in Haute Beauty 22
Slide 23: Q2 2023 Financials – Balance Sheet
June 30, 2023 December 31, (Unaudited) 2022 Q2 2023 ASSETS Current assets: Cash and cash equivalents $ 18,479 $ 10,192 Trade accounts receivable, net of allowance of $555 and $668 12,072 10,602 Financials – Income tax receivables 7,752 7,545 Other receivables 315 99 Inventories, net of provision for
Slide 24: Q2 2023 Financials – Statement of Operations
Q2 2023 Financials – Statement of Operations 24
Slide 25: Q2 2023 Financials – EBITDA
The Company has presented the following non-GAAP financial measure in Q2 2023 this press release: adjusted EBITDA. The Company defines adjusted EBITDA Financials – as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amor
Slide 26: ESG Fundamentals – Marketing, Training, Product Design and Certification
ESG Fundamentals – Marketing, Training, Product Design and Certification • The strategy around our marketing has been focused on evidenced-based medicine, user education, and patient safety. • Training on compliant and responsible promotion is provided to all new employees, as well as existing emplo
Slide 27: ESG Fundamentals – Education, Diversity and Community Outreach
ESG Fundamentals – Education, Diversity and Community Outreach • To ensure that all patients have a safe experience with our products, we created an educational program that is offered to every physician user after purchase of our equipment. We pride ourselves on safety and have a team of clinical n